 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
|
|
|
|
May 11, 1998 Company Press Release Phytera and Galileo Sign Research, Development and Marketing AgreementUnder the terms of the agreement, Phytera is providing ExPAND® plant cell culture extracts and mMARINE® marine microorganism extracts for screening in Galileo’s Metabolic Target Array Query (MTAQ™) proprietary assay systems for the detection of anti-ischemic agents. Phytera will provide natural product chemistry for the bioassay-guided fractionation, isolation and structural identification of active compounds, while Galileo will provide experimental pharmacology support for the in vivocharacterization of lead compounds. Phytera may also provide synthetic chemistry support through its combinatorial chemistry subsidiary, Phytera Symbion ApS of Copenhagen, Denmark. “Treatment of ischemic diseases represents a major unmet medical need,” said Malcolm Morville, Ph.D., President and CEO of Phytera. “This partnership brings together Phytera’s unique library of chemically-diverse natural product extracts with Galileo’s proprietary screening technology that target these important diseases. We are excited about the potential to identify novel lead compounds and candidates that address serious and inadequately treated diseases such as stroke and MI. Further, the Galileo collaboration is another example of Phytera’s strategy to exploit our unique library of chemically-diverse natural product extracts through partnerships with companies that possess innovative, proprietary screening technologies. We expect to execute more agreements of this type in the near future.” “The discovery of new anti-ischemic agents has been limited by the absence of targeted methodologies to screen, identify, and conduct analoging of lead compounds. The strategic alignment of Galileo’s proprietary MTAQ™ system and Phytera’s unique natural product libraries will enable the rapid discovery of new classes of anti-ischemic agents,” said Guy Miller, M.D., Ph.D., Chairman and CEO of Galileo Laboratories, Inc. “Through this alliance we will target the development of drugs to treat the millions of patients that suffer from ischemic diseases each year.” About Galileo LaboratoriesGalileo Laboratories, Inc. is a biotechnology company headquartered in Sunnyvale, CA. The Company is focused on the identification and development of drugs that modulate cell energy metabolism for the treatment and prevention ischemic disease. Galileo’s proprietary technology, the Metabolic Target Array Query (MTAQ™) system, allows the interrogation of complex, dynamic metabolic pathways. About PhyteraPhytera, Inc. is a biotechnology company headquartered in Worcester, Massachusetts, with wholly owned subsidiaries in Sheffield, UK, Copenhagen, Denmark and Tåstrup, Denmark. The Company is focused on applying novel technology platforms to the identification and optimization of new lead structures and drug candidates for pharmaceutical application. Phytera has allied its plant and marine microbial culture technologies with its innovative high throughput screening and combinatorial chemistry capabilities to create and integrated discovery platform. Infectious disease products from the program are currently in preclinical development. Additionally, Phytera seeks to leverage its technologies via external collaborations and to date has signed agreements with Amersham International plc, Tsumura & Co., and Galileo Laboratories, Inc. ContactPeter
Leighton, Vice President Marketing
|
